ClinicalTrials.gg
RecruitingNCT07107529Updated Apr 15, 2026

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

A Phase 2 interventional study of Teclistamab and Talquetamab in Multiple Myeloma (MM), sponsored by European Myeloma Network B.V.. Recruiting at 29 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by European Myeloma Network B.V. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing teclistamab in Multiple Myeloma — 22 open to participants now, 32 under way, 9 of them phase 3. teclistamab · Multiple Myeloma.

Planned enrollment
14th of 33
150 · median 80
Started
2025
with 6 others
Phase 2
16 of 33
13 open now
Primary completion
2029-04
later than 22 of 31 live
Registered
24th of 33
by date
Lead sponsor
2 of 33
European Myeloma Network B.V.

Among the 33 studies testing teclistamab in Multiple Myeloma, this one is the 14th largest by planned enrollment, is one of 7 that started in 2025, is one of 16 in phase 2, reaches primary completion later than 22 of the 31 other live ones, and was the 24th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

22 of the 33 studies testing teclistamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About teclistamab

teclistamab: first FDA approval 2022 (TECVAYLI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing teclistamab in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab.

The main purpose of this study is to determine the progression free survival at 18 months in patients treated with teclistamab and daratumumab (Cohort 1) or talquetamab and daratumumab (Cohort 2).

Read the detailed description

This study will consist of 4 phases:

  • Initial treatment phase where patients will receive fixed duration of Tec-Dara or Tal-Dara.
  • TFI.
  • Re-treatment phase, where patients with confirmed PD will continue treatment with Tec-Dara or Tal-Dara per their assignment in the initial treatment phase.
  • Post-treatment follow-up phase.
03

Conditions studied

  • Multiple Myeloma (MM)

Browse trials for

Keywords

  • Newly diagnosed multiple myeloma (NDMM)
  • Frail patient
  • Talquetamab
  • Teclistamab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is ≥18 years of age and capable of giving and must sign an informed consent form (ICF), indicating that they understand the purpose of, and procedures required for, the study and is willing to participate in the study
  2. Newly diagnosed and treatment-naïve patients with a confirmed diagnosis of MM with according to IMWG criteria
  3. Measurable disease defined as M-protein in the serum (≥1 g/dL) or serum free light chain assay ≥10 mg/dL [≥100 mg/L] and abnormal serum immunoglobulin kappa/lambda FLC ratio
  4. Frail according to the Simplified IMWG frailty index
  5. Have clinical laboratory values meeting defined range
  6. Patients of must agree to use adequate/highly effective from the time of signing the informed consent form through 3 months after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Non-secretory MM or by urine or plasmacytoma only
  2. Central nervous system involvement of myeloma
  3. Significant pulmonary dysfunction
  4. Stroke, , or seizure within 6 months of eligibility
  5. Evidence of active systemic viral, fungal, or bacterial infections, requiring systemic antimicrobial therapy
  6. and Hepatitis infections
  7. Exclude for any of the following:

    1. Any history of other than MM which is considered at high risk of recurrence requiring treatment or a malignancy that has been treated with chemotherapy currently affecting bone marrow capacity.
    2. Any active malignancy (ie, progressing or requiring treatment change in the last 24 months) other than multiple myeloma.
  8. Active disease requiring systemic therapy within 6 months before eligibility
  9. or life-threatening allergies, , or intolerance to any study treatment or its (refer to IB and most recently applicable RSI)
  10. Extensive radiotherapy within 14 days or focal radiation only within 7 days of eligibility
  11. Current or active therapy for multiple myeloma or received a cumulative dose equivalent to >40 mg dexamethasone within the 14 days prior to C1D1
  12. Received a ≤4 weeks before eligibility. Non-live vaccines or non-replicating authorized for emergency use (eg, COVID-19) are allowed
  13. Received a strong inducer or use of St. John's wort ≤5 half-lives prior to dosing
  14. Patient had major surgery or significant traumatic injury within 2 weeks prior to eligibility. Kyphoplasty or Vertebroplasty is not considered major surgery
  15. Have received an drug (including investigation vaccines) or used an invasive investigational medical device \<4 week or 5 PK half-lives, before eligibility or is currently enrolled in an interventional investigational study except if only long-term survival data are collected
  16. Concurrent medical or psychiatric condition or disease (eg, uncontrolled diabetes, alcohol or drug abuse, severe dementia or altered mental status), that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participation in the study
  17. Any other issue that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site, to understand or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the patient (eg,, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Tec-Dara

    Drug: Teclistamab · Drug: Daratumumab

  • Experimental
    Cohort 2

    Tal-Dara

    Drug: Talquetamab · Drug: Daratumumab

Interventions

  • Teclistamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.

  • Talquetamab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.

  • Dartumumab will be administered via a subcutaneous injection (SC), fixed duration and will be retreated until disease progression or intolerable toxicity.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) per IMWG criteria

    defined as the time from the date of randomization until the first occurrence of disease progression or death from any cause, whichever occurs earlier, where disease progression is determined per IMWG criteria.

    Time frame: 18 months

Secondary outcomes

  1. Overall Survival (OS)

    Measured from the date of from randomization to the date the subject's death.

    Time frame: 9 years

  2. Minimal Residual Disease (MRD) negativity rate

    Minimal Residual Disease (MRD) negative as determined by NGF at 10\^-5 sensitivity level per International Myeloma Working Group (IMWG) criteria.

    Time frame: 18 months

  3. Minimal Residual Disease (MRD) negative CR

    Minimal Residual Disease (MRD) negative Complete Remission (CR) at the end of fixed treatment duration status as determined by NGF at 10\^-5 sensitivity level and who also achieve CR or better per International Myeloma Working Group (IMWG) criteria.

    Time frame: 18 months

  4. Sustained Minimal Residual Disease (MRD) negative CR

    Sustained MRD-negative CR is defined as patients with CR or better who sustain MRD-negative status, as determined NGF at 10\^-5.

    Time frame: 9 years

  5. IMWG best response

    To evaluate the proportion of IMWG best response achieved by a patient during the study. Subject will be classified as Not Evaluable (NE) if they will not have any evaluable response assessment.

    Time frame: 18 months

  6. Time to response

    Time from the date of randomization to the date of first documentation of a confirmed response (partial response) as per IMWG response criteria, for patients who have PR or better as their best response.

    Time frame: 9 years

  7. Time to best response

    Time from the date of randomization to the date of first best response as per IMWG response criteria.

    Time frame: 9 years

  8. Event free survival (EFS)

    Time from the date of randomization to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause or treatment discontinuation due to toxicity, whichever occurs first.

    Time frame: 9 years

  9. Progression Free Survival 2 (PFS2)

    Time from the randomization date to the date of event, which is defined as death from any cause or progression disease on the next line of therapy, whichever occurs first.

    Time frame: 9 years

  10. Time to Next Treatment (TNT)

    Time from the randomization date to the date of event, which is defined as the start of the next line of therapy or death from any cause, whichever occurs first.

    Time frame: 9 years

  11. Adverse Events

    Incidence and severity of Adverse Events during initial therapy, Treatment-Free-Interval (TFI) and after restarting therapy.

    Time frame: 9 years

  12. Discontinuation

    Discontinuation rate and cause due to treatment related toxicity during initial therapy and after restarting therapy, including overall discontinuation rate, discontinuation rate of daratumumab, teclistamab and talquetamab.

    Time frame: 9 years

  13. Change from Baseline in Health-Related Quality of Life as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score

    The EORTC QLQ-C30 includes 30 items in 5 functional scales, 1 global health status scale, 3 symptom scales, and 6 single symptom items. The item and scale scores are transformed to a 0 to 100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms.

    Time frame: Up to 9 years

  14. Change from Baseline in Health-Related Quality of Life as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Myeloma 20 (EORTC-MY-20) Scale Score

    The EORTC-QLQ-MY20 is a specialised tool designed to assess the quality of life in myeloma patients. Scores are linearly transformed to a 0-100 scale, where higher scores on the symptom scales indicate worse outcomes.

    Time frame: Up to 9 years

  15. Change from Baseline in Health-Related Quality of Life as Assessed by Activities of Daily Living (ADL) questionnaire

    The ADL questionnaire assesses functional status by measuring independence in six daily activities. The ADL scale is scored from 0 to 8, where higher scores indicate greater independence with daily activities.

    Time frame: Up to 9 years

  16. Change from Baseline in Health-Related Quality of Life as Assessed by Instrumental Activities of Daily Living (IADL) questionnaire

    The IADL assesses instrumental activities of daily living, including telephone use, laundry, shopping, food preparation, and mode of transportation. The IADL scale is scored from 0 to 8, with higher scores indicating greater independence.

    Time frame: Up to 9 years

  17. Change from Baseline in Health-Related Quality of Life as Assessed by Scale of Subjective Total Taste Acuity (STTA)

    The STTA scale assesses the taste acuity during treatment. The STTA scale is scored from 0 to 4, where 4 indicates almost complete loss of taste acuity.

    Time frame: Up to 9 years

  18. Change from Baseline in the geriatric assessment as Assessed by Geriatric Depression Scale (GDS)

    The GDS scale assesses the depressive symptoms in frail elderly patients. The GDS scale is scored from 0 to 15. Score 1 point for each bolded answer. A score of 5 or more suggests depression.

    Time frame: Up to 9 years

  19. Change from Baseline in the geriatric assessment as Assessed by Mini Nutritional Assessment (MNA) questionnaire

    The MNA is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition. The MNA scale is scored from 1 to 30. A higher score represents good nutrition, a score less then 17 represents malnutrition.

    Time frame: Up to 9 years

  20. Change from Baseline in the geriatric assessment as Assessed by Mini-Mental State Examination (MMSE)

    The MMSE is an 11-question tool to assess mental status, testing five cognitive areas. The MMSE scale is scored from 1 to 30. A higher score represents good mental state.

    Time frame: Up to 9 years

  21. Change from Baseline in the geriatric assessment as Assessed by Geriatric Assessment in Hematology (GAH) scale

    The GAH scale predicts treatment tolerability in older patients diagnosed with hematological malignancies. The 30-item GAH scale was designed through a multi-step process to cover 8 relevant dimensions. Higher scores indicate a more frail or vulnerable patient.

    Time frame: Up to 9 years

07

Study locations

6 of 29 sites recruiting
  • IT-Ascoli Piceno-Ospedale Mazzoni [01-016]
    Ascoli Piceno, Italy
    Recruiting
  • IT-Bari-A.O.U. Consorziale Policlinico - Medicina Interna [01-018]
    Bari, Italy
    Not yet recruiting
  • IT-Bergamo-A.O. Papa Giovanni XXIII [01-003]
    Bergamo, Italy
    Not yet recruiting
  • IT-Bologna-A.O.U. di Bologna - Policlinico S. Orsola Malpighi [01-004]
    Bologna, Italy
    Not yet recruiting
  • IT-Bolzano-Ospedale di Bolzano - Azienda Sanitaria dell'Alto Adige [01-021]
    Bolzano, Italy
    Not yet recruiting
  • IT-Como-Ospedale Classificato Valduce [01-104]
    Como, Italy
    Recruiting
  • IT-Milano-Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico [01-039]
    Milan, Italy
    Not yet recruiting
  • IT-Milano-Ospedale S. Carlo Borromeo [01-105]
    Milan, Italy
    Recruiting
  • IT-Novara-A.O.U. Maggiore della Carità [01-010]
    Novara, Italy
    Recruiting
  • IT-Pescara-Azienda USL di Pescara P.O. dello Spirito Santo [01-053]
    Pescara, Italy
    Recruiting
  • IT-Roma-ASL Roma 1 [01-101]
    Roma, Italy
    Not yet recruiting
  • IT-Roma-Policlinico Umberto I - Università 'Sapienza' [01-013]
    Roma, Italy
    Not yet recruiting
  • IT-Torino-A.O.U. Città della Salute e della Scienza di Torino-SSD Clinical trials [01-001]
    Torino, Italy
    Not yet recruiting
  • IT-Varese-Ospedale di Circolo [01-111]
    Varese, Italy
    Not yet recruiting
  • NL-Amsterdam-Vrije Universiteit Medical Center (VUMC) [02-007]
    Amsterdam, Netherlands
    Not yet recruiting
  • NL-Arnhem-Rijnstate Hospital [02-009]
    Arnhem, Netherlands
    Not yet recruiting
  • NL-Enschede-Medisch Spectrum Twente [02-024]
    Enschede, Netherlands
    Not yet recruiting
  • NL-Groningen-University Medical Center Groningen [02-030]
    Groningen, Netherlands
    Not yet recruiting
  • NL-Nieuwegein-S. Antonius Hospital [02-038]
    Nieuwegein, Netherlands
    Not yet recruiting
  • NL-Schiedam-Franciscus Vlietland Hospital [02-049]
    Schiedam, Netherlands
    Not yet recruiting
  • NL-Sittard-Geleen-Zuyderland Medical Center [02-058]
    Sittard, Netherlands
    Not yet recruiting
  • NL-Den Haag-Haga Ziekenhuis [02-016]
    The Hague, Netherlands
    Not yet recruiting
  • NL-Zwolle-Isala Klinieken [02-057]
    Zwolle, Netherlands
    Not yet recruiting
  • NO-Oslo-Oslo University Hospital [23-007]
    Oslo, Norway
    Not yet recruiting
  • NO-Tønsberg-Vestfold Hospital Trust [23-012]
    Tønsberg, Norway
    Not yet recruiting
  • ES-Barcelona-H.U. Vall d'Hebrón [06-002]
    Barcelona, Spain
    Not yet recruiting
  • ES-Las Palmas-H.U. de Gran Canaria Dr Negrín [06-030]
    Las Palmas, Spain
    Not yet recruiting
  • ES-Murcia-H.U. Virgen de la Arrixaca [06-016]
    Murcia, Spain
    Recruiting
  • ES-Salamanca-H.U. de Salamanca [06-021]
    Salamanca, Spain
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2029, 40 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 40 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 6, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Apr 2029
CompletionEst.
Feb 2034
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07107529
Lead sponsor
European Myeloma Network B.V.
Collaborators
EMN Trial Office S.r.l. Impresa Sociale, HOVON - Dutch Haemato-Oncology Association, PETHEMA Foundation, Nordic Myeloma Study Group, Janssen Pharmaceutica N.V., Belgium
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Dec 12, 2025
Primary completion
Apr 2029 (estimated)
Completion
Feb 2034 (estimated)
Last update
Apr 15, 2026

Study contacts

Clinical Trial Office
Contact
amministrazione@emnresearch.it
+390110243236
Sonja Zweegman
principal investigator · Vrije Universiteit Medical Center (VUMC)
Maria-Victoria Mateos
principal investigator · University of Salamanca
Fredrik Schjesvold
principal investigator · Oslo University Hospital
Alessandra Larocca
principal investigator · A.O.U. Città della Salute e della Scienza di Torino
Niels van de Donk
principal investigator · Vrije Universiteit Medical Center (VUMC)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Teclistamab · Talquetamab

Start the discussion